{
  "docId": "019de073-c7d4-73ef-8fef-22f9b5017668",
  "docSlug": "c95aa30aee69a466f8f903e1480a3b33",
  "documentTitle": "Larimar Therapeutics | Investor Presentation Deck | 32 slides",
  "authorId": "larimar-therapeutics",
  "authorName": "Larimar Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 32,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "The slide uses a simple three-row layout to summarize the drug's purpose, current data status, and future milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-c7d4-73ef-8fef-22f9b5017668/15",
  "deckHref": "/decks/019de073-c7d4-73ef-8fef-22f9b5017668",
  "deckJsonHref": "/decks/019de073-c7d4-73ef-8fef-22f9b5017668.json",
  "deckAnchorHref": "/decks/019de073-c7d4-73ef-8fef-22f9b5017668#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.03,
        "y": 0.22
      },
      "kind": "list",
      "text": "CTI-1601: Designed to address the root cause of Friedreich's ataxia by delivering mature FXN to mitochondria.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65da576f-cafd-4c6f-88c1-ee91e1c44535",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.03,
        "y": 0.7
      },
      "kind": "list",
      "text": "Next Steps: Initiate in Q4 2022 a Phase 2 dose exploration study in Friedreich's ataxia patients. Cohort 1 to evaluate 25 mg dose; dose escalation contingent on FDA review of cohort 1 data. Top-line data from both cohorts expected in 2H 2023.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9321e7a9-0ddf-4645-90dd-ca15a9c7b29c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.03,
        "y": 0.45
      },
      "kind": "list",
      "text": "Clinical POC Data: Daily dosing of 50 mg or 100 mg of CTI-1601 for at least 7 days resulted in buccal cell FXN levels that met or exceeded those expected in phenotypically normal heterozygous carriers.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bdd8d093-b462-4dde-acbe-02826a47c22f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.43,
        "y": 0.94
      },
      "kind": "source-note",
      "text": "POC: Proof-of-concept",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f50cab6-69dd-45de-91cb-3885fdda5108",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.75,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Summary: CTI-1601 Advancing to Phase 2 Trial",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d6f9afd2-2e61-4388-856f-ecd2ba0c3a0f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "ce6d0afd-8f93-42c4-8dd7-4ba4e88a45c1",
      "evidence": "This slide is titled 'Summary: CTI-1601 Advancing to Phase 2 Trial' and contains a summary of key points, which is typical of an executive summary.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}